PCNA and neoplasm: Mechanistically, melatonin's antiproliferative effects are evidenced by significant reductions in Ki-67+ and PCNA+ tumor cells32, underscoring its potential as both a preventive and therapeutic agent in hormone-responsive breast cancers.